News
The antibody treatment cocktail that can help Sri Lanka combat Covid-19 in high-risk patients

REGN-COV2, an antibody drug cocktail for the treatment of coronavirus patients by pharmaceutical giant Roche, has received Emergency Use Authorization and approval in the US, Europe, Switzerland, India and Japan. This antibody treatment was successfully administered to former US President Donald Trump after he contracted Covid-19 in October last year. The drug cocktail is projected to reduce Covid-19 hospitalizations by 70%.
REGN-COV2 is a cocktail of two monoclonal antibodies, Casirivimab and Imdevimab, and is used for the treatment of mild-to-moderate Covid-19 in high-risk patients. Monoclonal antibodies are two laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as a virus. Antibodies Casirivimab and Imdevimab were specifically designed against the spike protein of SARS-CoV-2, directed to block the virus’s attachment and entry into the human cells.
“Latest clinical trials results show the important medical benefit casirivimab and imdevimab (Roche antibody cocktail) may provide to people with Covid-19 by significantly reducing their risk of hospitalization and death. This is very important for us to manage our patients as well”, said Dr. Chintaka De Silva, Senior Consultant Physician, Sri Jayewardenepura Hospital.
Due to the distinct engineering of the two neutralising antibodies, the REGN-COV2 remains effective against widest spread variants and reduces the risk of losing its neutralising potency against any new emerging coronavirus variants.
The two-drug cocktail is to be administered for the treatment of mild-to-moderate Covid-19 in adults and paediatric patients (12 or older) who are at high risk of developing severe disease. High risk patients include those over 60 or those who are immunosuppressed, undergoing cancer treatment, bone marrow or organ transplant or having multiple illnesses such as cardiovascular disease, chronic lung or kidney disease, diabetes etc.
Roche’s phase III global trial using over 4,500 high-risk, non-hospitalised Covid-19 patients, met its primary target, showing that its approved combined dose of 1200 mg (600 mg of each drug) significantly reduced the risk of hospitalization or death by 70% and also shortened the duration of symptoms within one week. Further results showed that the cocktail reduced risk of symptomatic coronavirus infections by 81% and reduced asymptomatic patients progressing to symptomatic Covid-19 by 31%.
Former US President Donald Trump was given a higher dose of REGN-COV2 in its experimental stages back in October 2020 when he contracted the virus and was reported to have completed the infusion successfully without incident.
The cocktail has received Emergency Use Authorization (EUA) in several countries. USA was the first to grant approval to this drug in November 2020, where the antibody cocktail was authorized by the US Food and Drug Administration (FDA) under an EUA. This was followed by the scientific opinion of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in February 2021 that confirmed REGN-COV2 as a treatment option for patients with confirmed Covid-19 who do not require oxygen supplementation and who are at high risk of progressing to severe Covid-19. Switzerland also received the go-ahead by Swissmedic for distribution of the two-drug cocktail in April 2021.
India, the second worst affected country in the world, announced in early May that the Central Drugs Standards Control Organisation (CDSCO) has provided an EUA for Roche’s antibody cocktail in India and that the drug will be made available through leading hospitals and Covid treatment centres to curb the country’s rising and staggering numbers of coronavirus positive cases and deaths. Japan also confirmed that it has concluded agreements with Roche for the purchase of doses of the antibody cocktail, pending approval by health ministry, as a new effective addition to Japan’s Covid-19 treatment plan.
Experts believe that monoclonal antibodies would prove to be a game changer in the treatment of Covid-19 in the coming days and opines that the antibody cocktail drug is an excellent combination drug to check severe manifestations of the disease and the administration of it would only complement the ongoing vaccination drives in the country.
News
COPE discovers fake documents covering drug imports in 2022/23

The Parliamentary watchdog Committee on Public Enterprises (COPE) has found that there were fake documents regarding the importing of medicines under the emergency procurement system in 2022 and 2023.
This was revealed during a COPE meeting held at Parliament probing the transactions of the National Medicine Regulatory Authority (NMRA).
NMRA CEO Saveen Semage told the committee that several fake documents have been found due to the lack of registration of medicines.
Stating that six such fake documents were found last year alone, Semage said he had recorded statements regarding each of the documents with the Financial Crimes Investigation Division.
He revealed that, however, no investigations have been conducted yet into the incidents.
“We have documents with confessions from a woman accepting that fake documents had been made. However, a statement has not even been recorded from that woman yet,” he said.
Meanwhile, COPE member MP Asitha Niroshana Egoda Vithana also revealed that the highest number of waive-off registrations (WOR) for medicines had been obtained in 2022 and 2023.
He said 656 such WORs had been obtained in 2022 and 261 in 2023, adding that this proves that discrepancies have taken place during the emergency procurement of medicines during these periods.
Furthermore, Deputy Director General of the Medical Supplies Division of the Health Ministry, Dr. G. Wijesuriya said discussions are underway on allowing the State Pharmaceutical Corporation (SPC) to directly import essential medicines.He pointed out that it was essential to take a policy decision in this regard as a solution to mitigate such discrepancies.
News
Batalanda report tabled in parliament, forwarded to AG

The Batalanda Commission report was tabled in Parliament on Friday by the Leader of the House and Transport Minister, Bimal Ratnayake.
Minister Ratnayake announced that the government has decided to forward the report to the Attorney General for legal advice. Additionally, a Presidential Committee will be appointed to provide guidance and recommendations on how to proceed with the findings of the report.
Ratnayake said that the Cabinet of Ministers, along with President Anura Kumara Dissanayake, has made a policy decision to take necessary action in response to the report. He reassured the public that steps are being taken to ensure that such a dark chapter in the country’s history is never repeated.
Minister Ratnayake said that a two-day debate on the Batalanda Commission report will be scheduled in Parliament at an appropriate time, allowing for a detailed discussion on the report’s findings and recommendations.
The report, which will be printed in all three official languages—Sinhala, Tamil, and English—will be made available to the public in the near future. Ratnayake confirmed that printed copies would be provided to members of Parliament as well as the general public for their review.
The Leader of the House further revealed that there are 28 evidence volumes associated with the commission’s work, which will be submitted to Parliament at a later date for further scrutiny.
Ratnayake said that as entire country concerned of the Batalanda Commission’s findings, the government’s commitment to addressing the issues raised and preventing future atrocities stands clear. The next steps, including legal action and policy recommendations, will be shaped by expert advice and informed parliamentary discussions, he said.
News
CB Governor stresses need to assist crisis-hit construction industry

Governor of the Central Bank Dr. Nandalal Weerasinghe on Friday (14) emphasized the importance of promoting a sustainable and cost-effective construction industry in the country, highlighting key challenges and opportunities in the sector.
Speaking at ‘Construction Expo 2025’, Dr. Weerasinghe underscored the need for Sri Lanka to align with global trends in sustainable construction, integrating cost-effective energy solutions and eco-friendly building practices.
“I must say my views here are not necessarily as Governor of the Central Bank of Sri Lanka, but as a person looking at this construction industry and how this can be developed and what the issues are. Sustainability in construction is essential, not just for new projects but also for existing buildings,” he noted.
Dr. Weerasinghe acknowledged that the construction sector has been one of the hardest-hit industries due to multiple economic pressures in recent years including the decline in public investments, high material costs and the industry being dependent on government projects.
The CBSL Governor, who acknowledged that the government faced fiscal constraints, limiting infrastructure spending and delaying payments to contractors, said that however, the outstanding arrears had now been settled.
“Government did not have space to spend money for public investment, especially construction that had a significant impact on the industry in the last couple of years, plus the government inability to pay the arrears for a long period. That was an issue we all recognize that has been one of the adverse impacts the industry had in the past”, he expressed.
“Also the cost of materials went up significantly, partly because of foreign exchange shortages. As a result, the shortage had shot up the prices of construction materials, as well as depreciation of the currency, high interest rates, finance costs, and other factors. We all recognize that it had an adverse impact on the industry. It’s one of the worst affected industries because of all these factors.”
-
Opinion6 days ago
Insulting SL armed forces
-
News4 days ago
Alfred Duraiappa’s relative killed in Canada shooting
-
Foreign News20 hours ago
Search continues in Dominican Republic for missing student Sudiksha Konanki
-
Features3 days ago
Richard de Zoysa at 67
-
Editorial5 days ago
Ghosts refusing to fade away
-
Features3 days ago
SL Navy helping save kidneys
-
Features5 days ago
The Gypsies…one year at a time
-
Midweek Review4 days ago
Ranil in Head-to-Head controversy